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This study shows the evaluation the antiproliferative effect of the extract, fractions, and uncommon compounds isolated from
R. rosaefolius leaves. The compounds were identified by conventional spectroscopic methods such as NMR-H1 and C13 and
identified as 5,7-dihydroxy-6,8,4󸀠-trimethoxyflavonol (1), 5-hydroxy-3,6,7,8,4󸀠-pentamethoxyflavone (2), and tormentic acid (3).
Both hexane and dichloromethane fractions showed selectivity for multidrug-resistant ovary cancer cell line (NCI-ADR/RES) with
total growth inhibition values of 11.1 and 12.6 𝜇g/ml, respectively. Compound 1 also showed selective activity against the same cell
line (18.8 𝜇g/ml); however, it was especially effective against glioma cells (2.8 𝜇g/ml), suggesting that this compoundmay be involved
with the in vitro antiproliferative action.
1. Introduction
Many are the advances in drug discovery for cancer preven-
tion and treatment, but still there is a need for new therapies,
as the statistics for cancer incidence and death by cancer
worldwide are noteworthy [1]. Nature is an important source
of new molecules with biological activities; around 75% of
the anticancer agents are derived from or inspired by natural
products [2]. Rubus is the largest genus in the Rosaceae
family, which is used especially as ornamental plants and for
food, as it has tasty fruits. In the folk medicine, some species
are used to treat different diseases, particularly diabetes [3,
4]. Phytochemical and pharmacological studies have shown
that some species exert gastroprotective, antimicrobial, and
cytotoxic effects, without genotoxic effects [5–11]. Rubus
rosaefolius is popularly known as “red berry,” and its fruits
are consumed as food. Previous phytochemical investigations
revealed the presence of sterols and terpenoids, which exhib-
ited important antibacterial and antinociceptive activities
[12, 13]. In this study, we have isolated and structurally
characterized an uncommon methoxylated flavonol from
the methanolic extract of Rubus rosaefolius leaves. Flavonols
are an important class of compounds with many biological
activities, including anticancer [14]. It is postulated that
presence of 3-OH is essential for inhibition of topoisomerase
in several cancer cell lines and substantially influences several
mechanisms of antioxidant activity [14]. Also, methylation
of some hydroxyl groups enhances the cytotoxic activity of
some flavonols [14–16]. Bearing in mind the potential of
methoxylated flavonols as anticancer agents and the need of
new antiproliferative therapies, we evaluated the antiprolifer-
ative effect of the crude extract, fractions, and the uncommon
methoxylated flavonol (1) in eight human cancer cell lines.
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Figure 1: Molecular structure of compounds (1–3) obtained from Rubus rosaefolius leaves.
2. Results and Discussion
Dichloromethane (DCM) and hexane (HE) fractions of R.
rosaefolius leaves were subjected to a series of silica gel chro-
matography columns to obtain three compounds, a uncom-
mon methoxylated flavonol (1) along with the known com-
pounds 5-hydroxy-3,6,7,8,4󸀠-pentamethoxyflavone (2) and
tormentic acid (3) (Figure 1). All compounds were identified
by 1D and 2D RMN analysis and comparison of physical
and spectroscopic data with those of literature [17, 18].
Compound 1 was obtained as a yellow crystal and showed
a [M]+ peak at m/z 360.3 in the electron impact ionization
mass spectroscopy (EIMS), corresponding to a molecular
formula C
18
H
16
O
8
. The IR spectrum showed the presence of
hydroxyl groups (3354 cm−1), a conjugated carbonyl group
(1624 cm−1), and aromatic rings (1500–1600 cm−1). The 1H
NMR spectrum (Table 1) revealed three downfield singlets
at 𝛿H 12.26, 10.38, and 9.56, all disappearing by addition of
D
2
O, suggesting the presence of three phenolic hydroxyls
one of which chelated. Also displayed two ortho coupled
doublets (2H each) at 𝛿H 8.24 and 𝛿H 7.17 suggesting p-
substituted aromatic rings, and three methoxyl groups at
𝛿H 3.79 (3H), 3.80 (3H), and 3.85 (3H). The 13C NMR data
and HMBC correlations in DMSO-d6 are reported in Table 1
and indicated that the protons at 8.24 (H-2󸀠,6󸀠) correlated
with the carbons at 𝛿 129.2 (C-2󸀠,6󸀠), 146.3 (C-2), and 160.5
(C-4󸀠). Similarly, protons at 7.17 (d, 𝐽 = 8.7Hz, H-3󸀠5󸀠)
correlated with carbons at 𝛿 114.2 (C-3󸀠5󸀠), 123.4 (C-1󸀠), and
160.5 (C-4󸀠), confirming a p-substituted B ring. Methoxylic
protons observed at 𝛿 3.85, 3.80, and 3.79 showed correlations
with aromatic carbons at 𝛿 127.7 (C-8), 131.0 (C-6), and
160.5 (C-4󸀠), respectively, demonstrating that the methoxylic
groups were located at C-6 and C-8 of ring A and C-
4󸀠 of ring B (Figure 2). All the data and comparison with
those reported previously and combined with other partial
structures, enabled this compound to be identified as 5,7-
dihydroxy-6,8,4󸀠-trimethoxyflavonol (1). At the best of our
Table 1: 1H and 13C NMR data of compound 1 in DMSO-d6.
Position 1H NMR 13C NMR HMBC
2 146.3
3 135.8
4 176.4
5 147.3
6 131.0
7 150.6
8 127.7
9 144.5
10 102.4
1󸀠 123.4
2󸀠, 6󸀠 8.24 d (9.0) 129.2 C-2, C-2󸀠6󸀠, C-4󸀠
3󸀠, 5󸀠 7.17 d (9.0) 114.2 C-1󸀠, C-3󸀠5󸀠, C4󸀠
4󸀠 160.5
OMe-4󸀠 3.80 s 55.4 C-4󸀠
OMe-6 3.79 s 60.2 C-6
OMe-8 3.85 s 61.1 C-8
OH-3 9.56 s
OH-5 10.38 s
OH-7 12.26 s C-6, C-9, C-10
𝛿 in PPM; 𝐽 in Hz; 1H NMR at 300MHz and 13C NMR at 75MHz.
knowledge, compound 1 was obtained by synthesis [19] and
isolated only once as natural product [20].
Initially, we evaluated the antiproliferative activity of the
crude extract against four cell lines such as U251, MCF7,
NCI-H460, and 786-0. The concentrations which inhibited
50% cell growth were 28.9, 29.6, 36.1, and 225.2 𝜇g/mL,
respectively. Considering these results, fractions and com-
pound 1 were tested for their antiproliferative activity against
eight human cancer cell lines and a nontumor cell line in
four concentrations (0.25, 2.5, 25, and 250𝜇g/mL), using
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Table 2: Antiproliferative activity of doxorubicin, hexane (HE), dichloromethane (DCM), and ethyl acetate (EA) fractions and compound 1
against human cancer cell linesa.
Total growth inhibition (TGI) (𝜇g/mL)b
Cell lines Doxorubicin HE DCM EA Compound 1
Glioma (U251) 4.1 35.4 51.1 >250 2.8
Breast (MCF-7) 0.62 45.2 17.8 >250 55.8
Multidrug-resistant ovary carcinoma
(NCI-ADR/RES) 9.1 12.6 11.1 >250 18.8
Kidney (786-0) 0.46 30.7 19.3 >250 15.8
Lung, non-small cells (NCI-H460) 4.3 56.3 135.0 >250 14.1
Ovary (OVCAR-3) 2.4 46.1 89.7 >250 14.5
Colon (HT-29) 1.3 28.2 24.4 >250 >250
Leukemia (K-562) >25 >250 250.0 >250 17.5
Nontumoral keratinocyte (HaCat) 0.79 10.4 25.8 >250 21.4
aAssessed by the sulforhodamine B (SRB) assay. bTGI values represent the concentration necessary (𝜇g/mL) for total inhibition of cancer cell proliferation.
Values were determined through nonlinear regression analysis using the ORIGIN 8.0 (OriginLab Corporation). Dose range tested: 0.25 to 250 𝜇g/mL.
Experiment was conducted in triplicate.
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Figure 2: Molecular structure and significant long-range correla-
tions observed in 1H-13C HMBC for compound 1 obtained from
Rubus rosaefolius leaves.
doxorubicin as positive control. Results are summarized in
Table 2 and were expressed as the concentration required
for completely inhibiting the cancer cell line growth after 48
hours of exposure to the samples (total growth inhibition,
TGI).
As shown in Table 2, DCM and HE fractions demon-
strated antiproliferative activity formost of the human cancer
cell lines evaluated. DCM fraction was more potent than HE
fraction, showing selectivity for breast (MCF-7), multidrug-
resistant ovary carcinoma (NCI-ADR/RES), kidney (786-
0), and colon (HT-29), with TGI (total grown inhibition)
values of 17.8, 11.1, 19.3, and 24.4𝜇g/mL, respectively. On
the other hand, ethyl acetate fraction (EA) did not demon-
strate significant activity in any of the concentrations tested.
Regarding the anticancer activity of hexane fraction, it can
be partially attributed to compound 3, which is reported to
have a potent free radical scavenging ability and considerable
antiproliferative activity against MCF-7 and HepG2 cell lines
[21]. Considering that compounds 1 and 2 were isolated
from DCM fraction and that there are already reports of
the anticancer activity of tormentic acid and its derivatives
[22, 23], only compound 1 was evaluated against the same
cell lines. As can be observed, compound 1 demonstrated in
vitro antiproliferative effects for glioma (U251), multidrug-
resistant ovary carcinoma (NCI-ADR/RES), kidney (786-0),
lung (NCI-H460), ovary (OVCAR-3), and leukemia cells
(K-562), with TGI values of 2.8, 18.8, 15.8, 14.1, 14.5, and
17.5 𝜇g/mL, respectively (Table 2). Despite being less potent
than DCM fraction for breast cancer cell line (MCF-7), the
isolated compound exhibited better in vitro antiproliferative
activity, being especially potent for glioma, with a TGI value
close to that of the positive control, doxorubicin. Glioblas-
toma multiform (GBM) is the most common primary tumor
of the central nervous system (CNS), and its occurrence
in older age groups has increased in recent decades, with
treatment or cure presenting a challenge to the scientific
community [24].
Although extract and fractions antiproliferative effect
may be attributed to the presence of several compounds, these
results suggest that this uncommon methoxylated flavonol
may be more closely involved with the in vitro anticancer
activity. Although some studies have demonstrated the anti-
cancer activity of Rubus genus, no reports have been found
for R. rosaefolius, this study being the first one to describe the
antiproliferative activity of this specie.
3. Material and Methods
3.1. General. IR spectra were recorded on a BOMEM-
100 with Fourier-Transform Infrared (FT-IR, BOMEM, St.
Jean Baptiste, QB, Canada) spectrometer using KBr. EIMS
were recorded on Shimadzu Gas Chromatograph (QP-2010S
series, Kyoto, Japan) coupled with a mass spectrometric
detector equipped with a NIST08 software database. 1D and
2DNMR spectra were recorded on a Bruker AV-300 (Bruker,
Karlsruhe, Germany) in DMSO-d6. Chemical shifts (𝛿) are
expressed in ppm, and coupling constants are given in Hz.
3.2. Chromatographic Conditions. Recoated aluminum plates
silica gel 60F
254
(E. Merck, Darmstadt, Germany) for TLC
were used and visualized under UV at 254 and 366 nm and
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by spraying with anisaldehyde sulfuric and FeCl
3
reagents.
Column silica gel 70–230 mesh and flash silica gel 230–400
mesh (E. Merck, Darmstadt, Germany) were used for the
column chromatography. Melting points were determined
on a Micro-Quı´mica APF-300 apparatus (Micro-Quı´mica,
Floriano´polis, SC, Brazil) and are uncorrected. The purity
of the isolated compound was examined by thin layer
chromatography (TLC) using Merck silica gel precoated
aluminum plates (thickness = 200𝜇m) and several solvent
systems of different polarities. All the reagents and solvents
used were of analytical grade and were purchased from
Sigma-Aldrich Co. (St. Louis, MO, USA) and Merck KGaA
(Darmstadt, Germany).
3.3. In Vitro Anticancer Activity Assay. Human tumor
cell lines, U251 (glioma), MCF-7 (breast), NCI-ADR/RES
(multidrug-resistant ovary), 786-0 (kidney), NCI-H460
(lung, non-small cells), OVCAR-3 (ovary), HT-29 (colon),
and K-562 (leukemia) were kindly provided by the United
States National Cancer Institute (NCI). Nontumor cell line
HaCat (human keratinocytes) was donated by Professor Dr.
Ricardo Della Coletta, FOP/UNICAMP. Stock cultures were
grown in medium containing 5mL of RPMI 1640 (GIBCO
BRL) supplemented with 5% fetal bovine serum (GIBCO
BRL). Penicillin (100U/mL) and streptomycin (100 𝜇g/mL)
were added to experimental cultures. Cells in 96-well plates
(100 𝜇L cells well-1) were exposed to sample concentrations
in DMSO/RPMI (0.25, 2.5, 25, and 250 𝜇gmL−1) at 37∘C, 5%
of CO
2
in air for 48 h. Final DMSO concentration did not
affect cell viability. Doxorubicin hydrochloride (0.1mg/mg;
Europharma) was adopted as a positive control (0.025, 0.25,
2.5, and 25𝜇g/mL). Afterwards, cells were fixed with 50%
trichloroacetic acid and cell proliferation was determined
by spectrophotometric quantification (540 nm) of cellular
protein content using sulforhodamine B assay [25]. In this
assay, the cell population density is measured at time zero
(when samples are added) thus allowing the calculation of the
concentrations that promote total growth inhibition (TGI).
These concentrations are calculated from T = T0, in which
the amount of protein at the end of sample incubation (T)
is equal to the amount at the beginning (T0) [26]. Using
the concentration-response curve for each cell line, TGI
(total growth inhibition) was determined through nonlinear
regression analysis using software ORIGIN 8.0 (OriginLab
Corporation) [26]. Experiment was conducted in triplicate.
3.4. Plant Material. The R. rosaefolius plant material was
collected in the town of Itaja´ı, SC, Brazil (26∘ 54󸀠 28󸀠󸀠 S; 48∘
39󸀠 43󸀠󸀠W) in March 2013 and identified by Dr. Ademir Reis
(Botanical Department of the Federal University of Santa
Catarina). A voucher specimen was deposited at the Barbosa
Rodrigues Herbarium (Itaja´ı-SC) under number V.C. Filho
035.
3.5. Extraction and Isolation. Air-dried powdered leaves
(580 g) of R. rosaefolius were exhaustively extracted with
methanol (MeOH) at room temperature for seven days.
The macerates were filtered and concentrated under reduced
pressure in a rotatory evaporator, yielding 174.0 g of crude
methanol extract. The extract was suspended in MeOH-
H
2
O (90 : 10) mixture and subjected to liquid-liquid partition
using solvents of increasing polarity such as HE, DCM,
and EA. Part of the DCM fraction (4.5 g) was subjected
to column chromatography over silica gel and eluted with
DCM-MeOH (100 : 0-0 : 100) in increasing order of polarity,
yielding 164 fractions which were combined based on TLC
profiles. Fraction 31–41 (1.0 g) was rechromatographed using
the same solvent system, yielding new 99 subfractions, which
were pooled according to their similar chromatographic pro-
files. Subfractions 14–28 were then eluted with a mixture of
Hexane : Acetone (75 : 25), yielding 35 subfractions in which
subfractions 10–30 presented as a yellow crystal (35mg) and
were identified as 5,7-dihydroxy-6,8,4󸀠-trimethoxyflavonol
(1) by NMR, DEPT, HMBC, IR data in comparison with
those reported previously [19, 27]. Also in relation to
DCM fraction isolation, fractions 100–123 (985mg) from
first column were combined and rechromatographed using
DCM-MeOH (100 : 0-0 : 100) as solvent system, yielding 125
subfractions, which were pooled according to their similar
chromatographic profiles. Subfractions 45–47 presented as a
pure colorless crystal (18mg) andwere identified as tormentic
acid (3) based on IR, Mass, and NMR data in comparison
with those reported previously [18]. Similarly, part of the HE
fraction (9.04 g) was subjected to column chromatography
over silica gel and eluted with DCM-MeOH (100 : 0-0 : 100)
in increasing order of polarity to afford 123 fractions, which
were combined based on their TLC profiles. Fraction 49–
68 (2.12 g) was rechromatographed using the same solvent
system, yielding new 105 subfractions. Of these, fraction
69–71 (14.0mg) was rechromatographed using the same
solvent system, yielding new 20 subfractions. Subfractions 1–
6 presented as a yellow crystal (4.7mg) and were identified as
5-hydroxy-3,6,7,8,4󸀠-pentamethoxyflavone (2) based on IR,
Mass, and NMR data in comparison with those reported
previously [17].
3.5.1. 5,7-Dihydroxy-6,8,4󸀠-trimethoxyflavonol (1). Yellowish
solid; mp 295–297∘C; IR (KBr) 𝜆max 3354, 2970, 1664, 1629,
1220 cm−1; 1H NMR (300MHz, DMSO-d6) 𝛿 12.26 (1H, s,
C-7-OH); 10.38 (1H, s, C-5-OH); 9.56 (1H, s, C-3-OH); 8.24
(2H, d, 𝐽 = 9Hz, H-2󸀠6󸀠); 7.17 (2H, d, 𝐽 = 9Hz, H-3󸀠5󸀠); 3.85
(3H, s, C-8-OMe); 3.80 (3H, s, C-4󸀠-OMe); 3.79 (3H, s, C-6-
OMe); 13C NMR (75MHz, DMSO-d6) 𝛿 176.4 (C=O, C-4),
160.5 (C-4󸀠), 150.6 (C-7), 147.6 (C-5), 146.3 (C-2), 144.5 (C-
9), 135.8 (C-3), 131.0 (C-6), 129.2 (C-2󸀠6󸀠), 127.7 (C-8), 123.4
(C-1󸀠), 114.2 (C-3󸀠5󸀠), 102.4 (C-10), 61.1 (C-8-OMe), 60.2 (C-
6-OMe), 55.4 (C-4󸀠-OMe); EIMS m/z 360.3 [M]+ (calcd for
C
18
H
16
O
8
: 360.3148).
3.5.2. 5-Hydroxy-3,6,7,8,4󸀠-pentamethoxyflavone (2). Yellow-
ish solid; mp 119–123∘C; IR (KBr) 𝜆max 3241, 2985, 1752, 1546,
1239 cm−1; 1H NMR (300MHz, CDCl
3
) 𝛿 8.17 (2H, d, 𝐽 =
9Hz, H-2󸀠6󸀠); 7.06 (2H, d, 𝐽 = 9Hz, H-3󸀠5󸀠); 4.10 (3H, s, C-
7-OMe); 3.95 (6H, s, C-6-OMe, C-8-OMe) 3.90 (3H, s, C-4󸀠-
OMe); 3.87 (3H, s, C-3-OMe); 13C NMR (75MHz, CDCl
3
) 𝛿
179.3 (C=O, C-4), 161.9 (C-4󸀠), 156.1 (C-2), 152.9 (C-7), 149.2
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(C-5), 144.9 (C-9), 138.6 (C-3), 136.1 (C-6), 132.4 (C-8), 130.3
(C-2󸀠6󸀠), 122.8 (C-1󸀠), 114.3 (C-3󸀠5󸀠), 107.5 (C-10), 62.1 (C-
8-OMe), 61.7 (C-7-OMe), 61.2 (C-6-OMe), 60.1 (C-3-OMe),
55.4 (C-4󸀠-OMe); EIMSm/z 388.1 [M]+ (calcd for C
20
H
20
O
8
:
360.3680).
3.5.3. Tormentic Acid (3). White powder; mp 269–275∘C;
IR (KBr) 𝜆max 3450, 2900, 1688, 1500, 1100 cm
−1; 1H NMR
(300MHz, CD
3
OD): 𝛿 5.29 (1H, s, H-12), 4.62 (1H, br s, 19-
OH), 3.66 (1H, dd, 𝐽 = 11.1, 4.5Hz, H-2), 2.93 (1H, d, 𝐽 =
9.3Hz, H-3), 2.50 (1H, s, H-18), 1.35 (3H, s, H-27), 1.19 (3H,
s, H-29), 1.02 (3H, s, H-23), 1.00 (3H, d, 𝐽 = 6.4Hz, H-30),
0.94 (3H, s, H-26), 0.81 (3H, s, H-24), 0.79 (3H, s, H-25); 13C
NMR (75MHz, CD
3
OD) 182.4 (C28), 140.2 (C-13), 129.4 (C-
12), 84.7 (C-3), 73.7 (C-19), 69.7 (C-2), 56.8 (C-5), 55.2 (C-
18), 48.6 (C-9), 48.3 (C-1), 43.2 (C-20), 42.7 (C-14), 41.2 (C-
8), 40.7 (C-4), 39.4 (C-22), 39.2 (C-10), 34.2 (C-7), 29.7 (C-
15), 29.4 (C-23), 27.4 (C-21), 27.2 (C-30), 26.7 (C-16), 25.0 (C-
27), 24.9 (C-11), 19.8 (C-6), 17.6 (C-24), 17.6 (C-26), 17.2 (C-
25), 16.8 (C-29); EIMSm/z: 488.2 [M]+ (calcd for C
30
H
48
O
5
:
488.6991).
4. Conclusions
In summary, our results showed the presence of a uncommon
methoxylated flavonol identified as 5,7-dihydroxy-6,8,4󸀠-
trimethoxyflavonol along with two known compounds, 5-
hydroxy-3,6,7,8,4󸀠-pentamethoxyflavone and tormentic acid.
They also showed that the methanolic extract, hexane, and
dichloromethane fractions presented an interesting in vitro
antiproliferative profile. Trimethoxylated flavonol isolated
fromRubus rosaefolius leaves also showed promising antipro-
liferative profile, especially against glioma cell line, making
this compound of great interest in the search for new
chemotherapeutic agent.
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